Therapeutic Targeting in Ovarian Cancer: Nano-Enhanced CRISPR/Cas9 Gene Editing and Drug Combination Therapy

Area of Science:

• Oncology
• Molecular Biology
• Biotechnology

Background:

• Ovarian cancer is a leading gynecological malignancy with high recurrence rates, often due to drug resistance.
• Current treatment strategies are limited by refractory disease and the need for novel therapeutic approaches.
• Understanding gene functions and cancer progression mechanisms is crucial for developing effective treatments.

Purpose of the Study:

• To review therapeutic target genes and their mechanisms in ovarian cancer.
• To discuss advances in nano-based delivery systems for CRISPR/Cas9.
• To explore the potential of combining CRISPR/Cas9 with drug treatments for ovarian cancer.

Main Methods:

• Review of current literature on ovarian cancer genetics and treatment strategies.
• Analysis of CRISPR/Cas9 gene editing applications in cancer therapy.
• Evaluation of nano-based delivery systems for CRISPR/Cas9 efficacy and stability.
• Exploration of combination therapy approaches targeting drug resistance genes.

Main Results:

• CRISPR/Cas9 system demonstrates significant potential for ovarian cancer gene therapy and drug development.
• Targeting genes like BRCA1/2 and P53 can enhance therapeutic strategies.
• Nano-based delivery systems improve CRISPR/Cas9 stability and tumor-specific delivery.
• Combination of CRISPR/Cas9 with targeted drugs shows promise in overcoming drug resistance.

Conclusions:

• CRISPR/Cas9 gene editing offers a promising avenue for improving ovarian cancer treatment efficacy.
• Nano-delivery systems enhance the therapeutic potential of CRISPR/Cas9.
• Combining CRISPR/Cas9 with targeted drug therapies presents a viable strategy to combat drug-resistant ovarian cancer.